Last updated on January 2019

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma


Brief description of study

To estimate the clinical benefit of REGN2810 monotherapy for patients with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC) (Groups 1 and 3) or with unresectable locally advanced CSCC (Group 2), as measured by overall response rate (ORR), according to central review.

Clinical Study Identifier: NCT02760498

Contact Investigators or Research Sites near you

Start Over

Clinical Trials Administrator

Mount Sinai Comprehensive Cancer Center
Miami Beach, FL United States
2.25miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.